Breast Cancer Clinical Trials in Detroit

Showing 441-460 of 706 trials

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

NCT02593227

This Phase II trial evaluates the safety and immunogenicity of two doses of the Folate Receptor Alpha (FRα) peptide vaccine mixed with GM-CSF as a vaccine adjuvant, with or without a immune priming with cyclophosphamide, as a consolidation therapy after neoadjuvant or adjuvant treatment of patients with Stage IIb-III triple negative breast cancer (TNBC).

Breast Cancer

Marker Therapeutics, Inc.80 participantsStarted Apr 2016

Tampa, Florida, United States • Westwood, Kansas, United States • Baltimore, Maryland, United States +8 more locations

COMPLETEDPhase 3< 1 mile

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

NCT00878709

The purpose of this study is to investigate whether neratinib can further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer after adjuvant treatment with trastuzumab.

Breast Cancer

Puma Biotechnology, Inc.2,840 participantsStarted Jul 2009

Anniston, Alabama, United States • Birmingham, Alabama, United States • Phoenix, Arizona, United States +491 more locations

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Breast Cancer Trials in Other Cities

Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Delphinus SoftVue™ ROC Reader Study (DMT SV RRS3)

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

MarginProbe® System U.S. Post-Approval Study

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer

Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

Breast Mesh Used in Two-staged Breast Reconstruction

Other Conditions in Detroit